HOME >> BIOLOGY >> NEWS
UT Southwestern researchers identify enzyme deficiency responsible for some sudden infant death cases

DALLAS - August 27, 199 - The discovery by UT Southwestern Medical Center at Dallas researchers that an enzyme deficiency is responsible for some infant deaths attributed to Sudden Infant Death Syndrome (SIDS) could lead to new postnatal testing to identify those at risk.

"Our observations suggest that this deficiency is a severe disorder contributing to early infant death," said Dr. Michael J. Bennett, a professor of pathology and pediatrics at UT Southwestern and director of clinical chemistry at Children's Medical Center of Dallas. "The defect is a deficiency in the SCHAD - short-chain L-3-hydroxyacyl coenzyme A dehydrogenase - enzyme."

The findings were published in the July/August issue of Pediatric and Developmental Pathology.

The deficiency occurs during the breakdown of fatty acids derived from fat stores in the body. The body uses these fats as an energy source when its normal energy supply of glucose, which is converted into glycogen, is used up. In the event of fasting, infants tend to exhaust their limited glycogen supply quickly and begin using the stored fat, Bennett said.

The clinical consequences of SCHAD deficiency -- an inborn error of metabolism -- occur when fatty acids from the stored fats enter the liver and fail to generate energy or to produce ketones. Ketones are a vital energy source for the brain because it cannot use fatty acids, unlike the heart and skeletal muscle, which use fat directly.

"In these infants, fat can get into the liver, but it can't be metabolized and released," Bennett said. "Hence infants' brains starve from the deficit of ketones, and they become comatose."

The researchers examined 150 cases for this study. While only 2 percent were due to SCHAD deficiency, the researchers hope their findings will prevent at least a small portion of the unexpected fatalities previously described as SIDS cases by developing immediate postnatal testing that would identify infants with the enzyme deficienc
'"/>

Contact: Jennifer Haigh
jhaigh@mednet.swmed.edu
214-648-3404
UT Southwestern Medical Center
27-Aug-1999


Page: 1 2

Related biology news :

1. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative
2. UT Southwestern biochemist honored with NIH Directors Pioneer Award
3. RSV can increase the risk of asthma, UT Southwestern researchers find
4. Searle Scholars program awards $240,000 to UT Southwestern researcher
5. Two molecules work together to aid transport of immune cells, UT Southwestern researchers find
6. Biochemist becomes 15th UT Southwestern faculty member serving on National Academy of Sciences
7. UT Southwestern researchers reveal mechanisms of smooth-muscle contraction
8. Fetal lungs provide a signal initiating labor, UT Southwestern researchers find
9. UT Southwestern researchers cite recent advances in underlying causes of rare body-fat disorders
10. UT Southwestern researchers discover link that could aid in treatment of kidney cyst diseases
11. UT Southwestern research halts narcolepsy symptoms

Post Your Comments:
(Date:6/30/2015)... 30, 2015 Genisphere announced ... to help further develop Genisphere,s therapeutics capabilities and portfolio. ... having spent much of the last 25 years in ... Bioscience, and Johnson & Johnson. Tom started his career ... Biotech Corporate Finance. He graduated from Dartmouth College with ...
(Date:6/26/2015)... 26, 2015 ATL Technology, LLC, a top provider ... in single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Jose, Costa Rica ). This acquisition will ... with ATL Technology,s existing facility in Costa ...
(Date:6/25/2015)... , June 25, 2015  Imagine a tool specifically ... a healthier, happier life. That,s exactly what USANA,s ... do. The cutting-edge, portable health program provides a personalized ... to help improve your lifestyle and nutrition. ... and gala Wednesday night, USANA,s THA was honored with ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
(Date:7/2/2015)... , ... July 02, 2015 , ... ... and manufacturing of surgical instruments in Orthopedics, announced today the acquisition of ... the world's largest provider of surgical instruments to the Spine Industry. The acquisition ...
(Date:7/1/2015)... , July 1, 2015   Decision Resources ... cited advantages of Otezla are its oral administration, ... as reported by surveyed rheumatologists. Otezla was the ... the treatment of active psoriatic arthritis in ... standard of care includes conventional oral treatments including ...
(Date:7/1/2015)... ALTO, Calif. , July 1, 2015 /PRNewswire/ ... focused on the development of groundbreaking drugs to ... (ALS), announced today that Robert G. Miller ... Center at Sutter Health,s California Pacific Medical Center ... The ALS Association for $1.5 million to help ...
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business ... to lower the barriers to innovation in life sciences R&D. The Pistoia Alliance President’s ... cash prizes of US$15,000 and a period of expert mentorship from a senior industry ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
Cached News: